Glycemic Variability and Oxidative Stress: a Link Between Diabetes and Cardiovascular Disease?

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2014 Oct 15

PMID 25314300

Citations 81

Authors

Yoshifumi Saisho

Affiliations

Soon will be listed here.

Abstract

Diabetes is associated with a two to three-fold increase in risk of cardiovascular disease. However, intensive glucose-lowering therapy aiming at reducing HbA1c to a near-normal level failed to suppress cardiovascular events in recent randomized controlled trials. HbA1c reflects average glucose level rather than glycemic variability. In in vivo and in vitro studies, glycemic variability has been shown to be associated with greater reactive oxygen species production and vascular damage, compared to chronic hyperglycemia. These findings suggest that management of glycemic variability may reduce cardiovascular disease in patients with diabetes; however, clinical studies have shown conflicting results. This review summarizes the current knowledge on glycemic variability and oxidative stress, and discusses the clinical implications.

Citing Articles

Trajectory Analysis in FBG and the Incidence of Chronic Kidney Disease: A Nationwide Population-Based Study.

Park H, Na K, Hwang Y, Han S, Park K, Park H Biomedicines. 2025; 13(2).

PMID: 40002749 PMC: 11852470. DOI: 10.3390/biomedicines13020336.

Protocol for a randomized comparative effectiveness trial comparing a very low-carbohydrate diet to DASH diet for polycystic ovary syndrome: the SUPER (Supporting Understanding of PCOS Education and Research) trial.

Greenwell S, Jones A, Smith Y, Marriott D, Aikens J, Padmanabhan V Trials. 2024; 25(1):750.

PMID: 39516828 PMC: 11549875. DOI: 10.1186/s13063-024-08583-y.

Association between hyperglycemia at ICU admission and postoperative acute kidney injury in patients undergoing cardiac surgery: Analysis of the MIMIC-IV database.

Ruan J, Huang W, Jiang J, Hu C, Li Y, Peng Z J Intensive Med. 2024; 4(4):526-536.

PMID: 39310058 PMC: 11411430. DOI: 10.1016/j.jointm.2024.04.004.

Observational study on stability of within-day glycemic variability of type 2 diabetes inpatients treated with decoctions of traditional Chinese medicine.

Xing Y, Li P, Pang G, Zhao H, Wen T Front Pharmacol. 2024; 15:1378140.

PMID: 39101135 PMC: 11294233. DOI: 10.3389/fphar.2024.1378140.

Brain functional and structural changes in diabetic children. How can intellectual development be optimized in type 1 diabetes?.

Stanislawska-Kubiak M, Majewska K, Krasinska A, Wais P, Majewski D, Mojs E Ther Adv Chronic Dis. 2024; 15:20406223241229855.

PMID: 38560719 PMC: 10981223. DOI: 10.1177/20406223241229855.

References

Raz I, Wilson P, Strojek K, Kowalska I, Bozikov V, Gitt A . Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care. 2009; 32(3):381-6. PMC: 2646013. DOI: 10.2337/dc08-1671. View

Ley S, Hamdy O, Mohan V, Hu F . Prevention and management of type 2 diabetes: dietary components and nutritional strategies. Lancet. 2014; 383(9933):1999-2007. PMC: 4751088. DOI: 10.1016/S0140-6736(14)60613-9. View

Ogawa A, Hayashi A, Kishihara E, Yoshino S, Takeuchi A, Shichiri M . New indices for predicting glycaemic variability. PLoS One. 2012; 7(9):e46517. PMC: 3459933. DOI: 10.1371/journal.pone.0046517. View

Chiasson J, Josse R, Gomis R, Hanefeld M, Karasik A, Laakso M . Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003; 290(4):486-94. DOI: 10.1001/jama.290.4.486. View

Baraka-Vidot J, Guerin-Dubourg A, Dubois F, Payet B, Bourdon E, Rondeau P . New insights into deleterious impacts of in vivo glycation on albumin antioxidant activities. Biochim Biophys Acta. 2013; 1830(6):3532-41. DOI: 10.1016/j.bbagen.2013.01.019. View

Marfella R, Barbieri M, Ruggiero R, Rizzo M, Grella R, Licia Mozzillo A . Bariatric surgery reduces oxidative stress by blunting 24-h acute glucose fluctuations in type 2 diabetic obese patients. Diabetes Care. 2009; 33(2):287-9. PMC: 2809267. DOI: 10.2337/dc09-1343. View

Zhou J, Li H, Ran X, Yang W, Li Q, Peng Y . Reference values for continuous glucose monitoring in Chinese subjects. Diabetes Care. 2009; 32(7):1188-93. PMC: 2699703. DOI: 10.2337/dc09-0076. View

SCHLICHTKRULL J, Munck O, JERSILD M . THE M-VALVE, AN INDEX OF BLOOD-SUGAR CONTROL IN DIABETICS. Acta Med Scand. 1965; 177:95-102. DOI: 10.1111/j.0954-6820.1965.tb01810.x. View

Bonds D, Miller M, Bergenstal R, Buse J, Byington R, Cutler J . The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010; 340:b4909. PMC: 2803744. DOI: 10.1136/bmj.b4909. View

10.

Smith K, Shepherd J, Wakil A, Kilpatrick E . A comparison of methods for the measurement of 8-isoPGF(2α): a marker of oxidative stress. Ann Clin Biochem. 2011; 48(Pt 2):147-54. DOI: 10.1258/acb.2010.010151. View

11.

Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N . Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011; 364(9):829-841. PMC: 4109980. DOI: 10.1056/NEJMoa1008862. View

12.

Nathan D, McGee P, Steffes M, Lachin J . Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. Diabetes. 2013; 63(1):282-90. PMC: 3868040. DOI: 10.2337/db13-0782. View

13.

Nathan D, Cleary P, Backlund J, Genuth S, Lachin J, Orchard T . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25):2643-53. PMC: 2637991. DOI: 10.1056/NEJMoa052187. View

14.

Sassa M, Yamada Y, Hosokawa M, Fukuda K, Fujimoto S, Toyoda K . Glycemic instability in type 1 diabetic patients: Possible role of ketosis or ketoacidosis at onset of diabetes. Diabetes Res Clin Pract. 2008; 81(2):190-5. DOI: 10.1016/j.diabres.2008.04.009. View

15.

White W, Cannon C, Heller S, Nissen S, Bergenstal R, Bakris G . Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369(14):1327-35. DOI: 10.1056/NEJMoa1305889. View

16.

Zoungas S, Patel A, Chalmers J, de Galan B, Li Q, Billot L . Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010; 363(15):1410-8. DOI: 10.1056/NEJMoa1003795. View

17.

De Caterina R, Cipollone F, Filardo F, Zimarino M, Bernini W, Lazzerini G . Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E. Circulation. 2002; 106(20):2543-9. DOI: 10.1161/01.cir.0000038500.43292.d7. View

18.

Chow E, Bernjak A, Williams S, Fawdry R, Hibbert S, Freeman J . Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes. 2014; 63(5):1738-47. DOI: 10.2337/db13-0468. View

19.

Sawada T, Shiotani H, Terashita D, Nagasawa Y, Kim S, Koide M . Comparison of effects of α-Glucosidase inhibitors and glinide drugs on endothelial dysfunction in diabetic patients with coronary artery disease. Circ J. 2013; 78(1):248-55. DOI: 10.1253/circj.cj-13-0918. View

20.

Cangemi R, Loffredo L, Carnevale R, Perri L, Patrizi M, Sanguigni V . Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E. Eur Heart J. 2007; 29(1):54-62. DOI: 10.1093/eurheartj/ehm565. View